EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

HCC Summit 2019

 

14-16 February 2019 Lisbon
Close
N. Poster
Poster title
Applicant name
Status
  P07-01 efficacy and safety of transarterial radioembolization with yttrium-90 in patients with hepatocellular carcinoma in the context of real clinical practice Christie Perelló Received Received
  P01-01 The dual role of RIP3-dependent signalling in controlling steatosis and carcinogenesis in experimental non-alcoholic steatohepatitis Marta B. Afonso Received Received
  P06-01 Lymphocytes count predicts the evolution of patients with hepatocellular carcinoma treated with sorafenib Leonardo Gomes Da Fonseca Received Received
  P02-01 The role of Albumin-Bilirubin grade (ALBI) and Neutrophil-lymphocyte ratio(NLR) in predicting survival in patients with Hepatocellular carcinoma(HCC) Vinay kumar Balachandrakumar Received Received
  LBP-01 CDK12 inhibition mediates DNA damage and suppresses adaptive responses to sorafenib treatment in hepatocellular carcinoma Cun Wang Received Received
  P05-01 Expression of galectin 3 and the clinical presentation of Hepatocellular Carcinoma recurrence after liver transplantation Norma Filgueira Received Received
  P03-01 Efficacy of sorafenib and lenvatinib for hepatitis etiology: a network meta-analysis of phase III trial Andrea Casadei Gardini Received Received
  P06-02 HCC recurrence after DAA treatment in HCV patients. Maria Guarino Received Received
  P03-02 Thermal ablation is a safe and effective treatment for intrahepatic cholangiocarcinoma in patients with cirrhosis Alvaro Diaz-Gonzalez Received Received
  P05-02 Serum levels of protein induced vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) Silvia Gaia Received Received
  P01-02 Liver NK cells from NLG4 KO mice inhibited progressions of hepatocellular carcinoma of C57BL/6 mice model through decrease in p53 and AKT expressions Johnny Amer Received Received
  P07-02 Thyroid hormone inhibits hepatocellular carcinoma development by reverting the metabolic reprogramming of cancer cells ANDREA PERRA Received Received
  LBP-02 Attenuated XPO5-mediated export of pre-miRNA confers sorafenib resistance in HCC Zhongjie Lin Received Received
  P04-02 Hepatic epithelioid hemangioendothelioma: an international multicenter study Marco Sanduzzi Zamparelli Received Received
  P07-03 Lack of CCL2 limits the development of HCC in a model of obesity-associated carcinogenesis Benedetta Piombanti Received Received
  P01-03 pivotal role of xist in regulating immune checkpoint pd-1/pd-l1 through a shared pathway between mir-194-5p and mir-155-5p in hepatocellular carcinoma Sara Atwa Received Received
  P03-03 A novel versatile murine cholangiocarcinoma model via CRISPR/Cas9-mediated sequential oncogenic mutations of liver organoids Michael Dill Received Received
  P05-03 Molecular evaluation of skin proliferative lesions in patients with hepatocellular carcinoma under sorafenib treatment Leonardo Gomes da Fonseca Received Received
  P04-03 Validation of modified ALBI-T score as a prognostic model to evaluate Egyptian patients with hepatocellular carcinoma Omar Elshaarawy Received Received
  P06-03 Direct-acting antiviral treatment and recurrence of hepatocellular carcinoma: a single center experience Marco Guarracino Received Received
  LBP-03 The long non-coding RNA SNHG16 affects prognosis in hepatocellular carcinoma by regulating p62 expression Jian-Hong Zhong Received Received
  P07-04 circulating mir-4507 as a novel prognostic biomarker in hepatocellular carcinoma Muhammad Yogi Pratama Received Received
  P01-04 endocan versus alphafetoprotein as a novel biomarker in hepatitis C related cirrhosis with hepatocellular carcinoma Abdel Ghani Badran Received Received
  P02-04 clinical characteristics of liver cirrhosis and hepatocellular carcinoma occurring after fontan operation Eun Ju Cho Received Received
  P04-04 Oncological long term benefit in case of anatomic versus parenchyma-sparing resection for hepatocarcinoma: does the extension matter? A meta-analysis of high quality propensity matched and randomized studies. Simone Famularo Received Received
  LBP-04 Influence of sustained virological response in diagnostic performance of alpha-fetoprotein for hepatocellular carcinoma in patients with HCV-cirrhosis Ana Gómez-Outomuro Received Received
  P03-04 Liver polyploidization during NAFLD: a Gatekeeper against Replication Stress Romain Donne Received Received
  P05-04 Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: a real-life multicentre study Massimo Iavarone Received Received
  P06-04 The pattern of de novo hepatocellular carcinoma evolution in patients with hepatitis C virus following direct acting antiviral therapy needs to be clarified. Cassia Regina Guedes Leal Received Received
  P02-05 Patients with hepatocellular carcinoma (HCC) treated with sorafenib who develop adverse effects during the first 60 days present a characteristic immunologic profile Josep Corominas Argente del Castillo Received Received
  P01-05 The effect of socio-economic deprivation and distance to travel in the survival of patients with Hepatocellular carcinoma in Liverpool region(UK) Vinay kumar Balachandrakumar Received Received
  LBP-05 Influence of treatment with direct-acting antivirals in hepatocellular carcinoma development in patients with Hepatitis C Virus-related cirrhosis Ana Gómez-Outomuro Received Received
  P05-05 Experience in the use of sorafenib impacts on reasons leading to discontinuation and chance of long term response Luca Ielasi Received Received
  P03-05 Radioembolization with Yttrium-90 microspheres for intermediate-advanced hepatocellular carcinoma: a single centre real-life experience Joniada Doraku Received Received
  P04-05 Analysis of the HSD17B13:TA allelic variant as a protective factor towards hepatocellular carcinoma in patients with and without chronic hepatitis C Martina Fazio Received Received
  P06-06 Somatic mutations and clonal dynamics in healthy and cirrhotic human liver Matthew Hoare Received Received
  P04-06 Galectin 3 as a risk factor for recurrence of Hepatocellular Carcinoma after liver transplantation Norma Filgueira Received Received
  P05-06 The current status of ing treatment modalities for naiive hepatocellular carcinoma patients over 70 years old : Single-center experience Kyung Sik Kim Received Received
  P02-06 Dissecting the landscape of (epi-)genetic alterations during sequential evolution of liver cancer. Carolin Czauderna Received Received
  P07-06 yttrium -90 trans arterial radioembolisation (tare) is an effective treatment for the downstaging of patients with hepatocellular carcinoma: a monocentric experience in a tertiary center Helene Regnault Received Received
  P01-06 Anticlonogenic and apoptotic effect of metformin on cholangiocarcinoma cell line Gulden Baskol Received Received
  P03-06 Globally relevant models for hepatocellular carcinoma survival applicable before and after TACE Omar Elshaarawy Received Received
  LBP-06 Identification of novel epigenetic targets in the fibrotic stroma associated with HCC. Marina Barcena-Varela Received Received
  P05-07 fas and p53-upregulated modulator of apoptosis in hepatocellular carcinoma cellular death Rusdina Bte Ladju Received Received
  P04-07 Evaluation of LI-RADS v2018 by magnetic resonance in US-detected nodules 2cm in cirrhotics Alejandro Forner González Received Received
  LBP-07 Glycogen synthase 2 (GYS2) restricts tumor metastatic ability via attenuating autophagy and breaking glycogenic homeostasis in hepatocellular carcinoma Di Wu Received Received
  P06-07 External beam radiotherapy (EBRT) as an effective and safe treatment in all stages of hepatocellular carcinoma (HCC) with cirrhotic liver disease: a single western institution experience. Clémence Hollande Received Received
  P02-07 Safety, and tolerability abd efficacy of transarterial chemoemebolization using drug elutind microspheres loaded with antracyclines for the treatment of patients with unresectable hepatocellular carcinome : PARIS study? Elena Gonzalez Received Received
  P03-07 Non-parenchymal TREM2 halts hepatocarcinogenesis through the inhibition of liver inflammation and hepatocyte proliferation Ibone Labiano Received Received
  P01-07 Sorafenib-induced pancreatic atrophy and its clinical implication in patients with hepatocellular carcinoma Francesca Benevento Received Received
  P07-07 What are the predictive factors for long-term survivors with advanced hepatocellular carcinoma treated with sorafenib? Daniela Reis Received Received
  P04-08 Percutaneous Microwave (MW) ablation is better than Radiofrequency (RFA) to obtain complete response in cirrhotic patients with very early and early hepatocellular carcinoma Silvia Gaia Received Received
  P03-08 To cure or not to cure intermediate stage hepatocellular carcinoma beyond Milan Criteria: trans-arterial chemoembolization versus surgery in a multicentric matched cohort Simone Famularo Received Received
  P05-08 Clinical safety, tolerability and adverse events of special interest in a Phase Ib study of atezolizumab (atezo) bevacizumab (bev) in hepatocellular carcinoma (HCC) Michael Lee Received Received
  LBP-08 The EGF-HER2/ErBb2JNK axis drives intrahepatic cholangiocarcinoma (CCA) development Francisco Javier Cubero Received Received
  P02-08 Regulation of miRNA expression by Sorafenib in primary human hepatocytes and liver cancer cells Patricia De La Cruz-Ojeda Received Received
  P06-08 AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma Massimo Iavarone Received Received
  P07-08 Efficacy and safety of the combination of pravastatin and sorafenib as a new therapy for the treatment of advanced hepatocellular carcinoma Ioana Riaño Received Received
  P07-09 miR-21/PPARalpha activation in NASH promotes progression towards hepatocellular carcinoma Pedro Miguel Rodrigues Received Received
  P05-09 cRel is a novel tumour suppressor in Hepatocellular Carcinoma Jack Leslie Received Received
  P04-09 A multicentric study on real-life impact of nivolumab in patients with hepatocellular carcinoma Leonardo Gomes Da Fonseca Received Received
  P01-09 Treatment of BCLC-B hepatocellular carcinoma with transarterial chemoembolization with novel polyethylene glicol doxorubicin drug-eluting microspheres: a pharmacokinetic study Elena Gonzalez Received Received
  P02-09 NASH as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role: case-control study Stefania De Lorenzo Received Received
  P06-09 Capecitabine in advanced hepatocellular carcinoma: a multicenter experience Filippo Pelizzaro Received Received
  P03-09 comparison between rates of hepatitis c-related hepatocellular carcinoma recurrence in patients who received or not direct acting antiviral treatment Hend Shousha Received Received
  P01-10 beta-catenin signaling controls NKG2D ligands expression in liver tumorigenesis Mathilde Cadoux Received Received
  P05-10 The development of hepatocellular carcinoma is not predicted by genetic variants in caucasian compensated HBV cirrhotics treated by Entecavir of Tenofovir for 10 years Alessandro Loglio Received Received
  P07-10 Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma Stephanie Roessler Received Received
  P02-10 Dual CCR2/CCR5 antagonism as macrophage targeted therapy in experimental hepatocellular carcinoma Helena Degroote Received Received
  P04-10 Sulfatase-2 (SULF2) in the hepatocellular carcinoma microenvironment orchestrates disease progression and therapy resistance Misti McCain Received Received
  P03-10 Interventional targeting of Cyclin E1 during hepatocarcinogenesis limits stem cell traits and hepatic myeloid cell homing and attenuates cancer progression Roland Sonntag Received Received
  P06-10 recurrence of hepatocellular carcinoma in patients with complete response treated with direct acting antivirals in clinical practice Christie Perelló Received Received
  P06-11 line1 retrotransposons - key drivers of hepatocellular carcinoma via TGF beta signalling Bassier Zadran Received Received
  P04-11 Analysis of epithelial to mesenchymal transition markers expression in liver of mice fed high fat diet Katarzyna Mi&281;kus Received Received
  P03-11 AXL positive myeloid cells are expanded within tumours and in the peripheral circulation in patients with hepatocellular carcinoma Sujit Mukherjee Received Received
  P05-11 Impact of screening in the average survival time of cirrhotic patients with HCC Ana Rita Lopes Received Received
  P02-11 Polyploidy Spectrum: A new marker of HCC tumor classification Chantal Desdouets Received Received
  P07-11 Obeticholic acid decreased alpha-Feto-protein levels in HCC through Farnesoid X receptor (FXR) Ahmed Salhab Received Received
  P01-11 ESM-1 as a marker of macrotrabecular-massive hepatocellular carcinoma Julien Calderaro Received Received
  P05-12 Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis Rocio Macias Received Received
  P02-12 protein kinase erk5 modulates liver regeneration process in mice Giovanni Di Maira Received Received
  P04-12 CXCL5 induced by the synergy of transforming growth factor-beta and Axl signaling causes neutrophil extracellular trap formation in hepatocellular carcinoma Wolfgang Mikulits Received Received
  P06-12 survival and prognostic factors of patients with advanced hepatocellular carcinoma and treated with sorafinib Hend Shousha Received Received
  P03-12 Hepatocellular carcinoma systemic therapy: predictive factors of sorafenib benefit Sofia Tavares Received Received
  P07-12 Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease. Results from a prospective screening program. Marco Sanduzzi Zamparelli Received Received
  P01-12 Analysis and characterization of mitochondrial DNA mutations in The Cancer Genome Atlas hepatocellular carcinoma cohort Coada Camelia Received Received
  P01-13 Time varying mHAP III is the most accurate score in predicting survival in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemo-embolization (TACE) Claudia Campani Received Received
  P06-13 Predictive factors of tumor recurrence and overall survival in patients with hepatocellular carcinoma firstly treated by locoregional therapies: results of a retrospective cohort study. Ramy Younes Received Received
  P03-13 CEUS pattern of hepatocellular carcinoma: prognostic implication Eleonora Terzi Received Received
  P05-13 Imaging and Clinical Features of HCC nidus: A Retrospective Study Leonardo Pisani Received Received
  P07-13 Sorafenib for patients with recurrent hepatocellular carcinoma after liver transplantation: intrinsic resistance or not? Vito Sansone Received Received
  P04-13 The hepatocyte specific role of the NRF2/KEAP1 axis for HCC progression during chronic liver disease Antje Mohs Received Received
  P04-14 Clinical validation of the role of contrast-enhanced ultrasound in the EASL guidelines for the diagnosis of hepatocellular carcinoma LORENZO MULAZZANI Received Received
  P06-14 post-transplant de novo neoplasms: role of HCC in risk stratification SHALABY SARAH Received Received
  P01-14 Oncostatin M induces increased invasiveness and angiogenesis in hepatic cancer cells through HIF1-alpha-related release of VEGF-A Stefania Cannito Received Received
  P07-14 Sequential systemic treatment in advanced hepatocellular carcinoma prolongs median overall survival to more than three years. Kornelius Schulze Received Received
  P03-14 Efficacy and safety of thermal ablation in patients with hepatocellular carcinoma (HCC) and high comorbidity (hc) Maria Torner Received Received
  P05-15 Circulating neutrophils present a dysfunctional immunophenotype in patients with hepatocellular carcinoma João Maurício Received Received
  P03-15 Early experience with lenvatinib for the treatment of advanced hepatocellular carcinoma in real world practice in Japan Kaoru Tsuchiya Received Received
  P07-15 Dual role of C3G in hepatocarcinoma tumor growth and progression. Implication in the HGF/c-Met signaling pathway Celia Sequera Hurtado Received Received
  P04-15 Changes in the circulating miRNome profiles after therapy identify miRNA predictive biomarkers for HCC recurrence Devis Pascut Received Received
  P01-15 Milticentric prospective study of validation of angiogenesis polymorphisms in hepatocellular patients treated with sorafenib. Interim analysis of INNOVATE study Andrea Casadei Gardini Received Received
  P02-15 hepatocellular carcinoma identification models for patients with hcv-related chronic liver disease using data mining techniques Hend Shousha Received Received
  P02-16 Energymetabolism and cell motility/adhesion defect in circulating NK-cells frompatients with Hepatocellular Carcinoma Alessandra Zecca Received Received
  P01-16 Cancer stem cell sub-population drives resistance to anti-angiogenic therapies in hepatocellular carcinoma Darko Castven Received Received
  P04-16 Acquisition of stem cell-like features in human cholangiocarcinoma is associated with an oxidative metabolism Mirella Pastore Received Received
  P03-16 Combination of ubiquitin carboxy-terminal hydrolase L1 inhibition and Sorafenib treatment in experimental hepatocellular carcinoma dampens tumor aggressiveness and reduces in vitro functional liver cancer stem cell characteristics Astrid Vandierendonck Received Received
  P05-17 impact of interval between complete ablation of hepatocellular carcinoma and start of direct acting antivirals to manage chronic hepatitis C infection Hend Shousha Received Received
  P01-17 genetic variation in death receptor domain 4 (DR4) gene and the susceptibility to hepatitis-c related hepatocellular carcinoma Hend Shousha Received Received
  P02-17 mtdh/aeg-1/lyric promotes tumor proliferation and targeted drug resistance in hepatocellular carcinoma Shunjie Xia Received Received
  P03-17 Color Doppler and contrast-enhanced ultrasonography to manage hemorragic complications occurring after percutaneous thermal ablation of hepatocellular carcinoma. LETIZIA VERONESE Received Received
  P04-17 Long-term survivors in patients with hepatocellular carcinoma: an ITA.LI.CA. report Filippo Pelizzaro Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:30, Fri 8:30-15:00
02:07
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

HCC Summit 2019

 

14-16 February 2019 Lisbon
HELP LINE
Manage Orders
FAQs


Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 14/02/2019 TO 14/02/2020
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                  
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 11/02/2019
Upload Poster
Upload Oral Presentation of Video
Upload
Poster
Upload Oral
Presentation or Video




PosterSessionOnline
Logo Draft
 
Logo Cert